Introduction
Multiple sclerosis (MS), a chronic autoimmune disorder attacking the central nervous system, affects over 2.8 million people globally. Ublituximab—an investigational anti-CD20 monoclonal antibody—targets B-cells implicated in MS pathology. This analysis presents pivotal 5-year outcomes from the ULTIMATE open-label extension (OLE) study, building on initial phase 3 trials that demonstrated ublituximab’s superiority over teriflunomide (an established oral therapy) in reducing relapses and MRI lesions over two years.
